« Back Journal of Dermatological Science

Article in Press

Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-α and interferon-α

  • R. Bergman

      Affiliations

    • Department of Dermatology, Rambam Medical Center, Israel
    • Corresponding Author InformationCorresponding author at: Department of Dermatology, Rambam Medical Center, POB 9160, Haifa, 31096, Israel. Tel.: +972 4 8542610; fax: +972 4 8542951.
    • ,
  • M. Ramon

      Affiliations

    • Department of Dermatology, Rambam Medical Center, Israel
    • ,
  • G. Wildbaum

      Affiliations

    • Department of Immunology and The Bruce Rappaport Faculty of Medicine, and the Rappaport Family Institute for Research in the Medical Sciences ,Haifa, Israel
    • ,
  • E. Avitan-Hersh

      Affiliations

    • Department of Dermatology, Rambam Medical Center, Israel
    • ,
  • E. Mayer

      Affiliations

    • Department of Dermatology, Rambam Medical Center, Israel
    • ,
  • A. Shemer

      Affiliations

    • Department of Dermatology, Sheba Medical Center, Tel-Aviv, Israel
    • ,
  • N. Karin

      Affiliations

    • Department of Immunology and The Bruce Rappaport Faculty of Medicine, and the Rappaport Family Institute for Research in the Medical Sciences ,Haifa, Israel

Received 9 June 2009 ,Revised 25 August 2009 ,Accepted 29 August 2009. Published online 12 July 2010 Corrected Proof

References 

  1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873
  2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664–1675
  3. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1373
  4. Krueger JG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–592
  5. Youssef S, Wildbaum G, Maor G, Lanir N, Gour-Lavie A, Grabie N, et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C–C chemokines. J Immunol. 1998;161:3870–3879
  6. Wildbaum G, Karin N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther. 1999;6:1128–1138
  7. Wildbaum G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J Immunol. 2000;165:5860–5866
  8. Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N. C–C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest. 2000;106:361–371
  9. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol. 2002;169:2685–2693
  10. Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2002;168:5885–5892
  11. Wildbaum G, Nahir M, Karin N, Lanir N, Gour-Lavie A, Grabie N, et al. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity. 2003;19:679–688
  12. Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004;173:1171–1178
  13. Zohar Y, Wildbaum G, Karin N. Beneficial autoimmunity participates in the regulation of rheumatoid arthritis. Front Biosci. 2006;11:368–379
  14. Feldmann M, Brennan FM, Maini N. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol. 1996;14:397–440
  15. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44–47
  16. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today. 1993;14:483–486
  17. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmactyoid predendritic cells initiate psoriasis through interferon-α production. JEM. 2005;202:135–143
  18. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, et al. Increased sensitivity to interferon-α in psoriatic T-cells. J Invest Dermatol. 2005;125:936–944
  19. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146–151
  20. Kirby B, Boffa MJ, Nayak N, Gallatin WM, Martin S, Griffiths CE. The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis. Br J Dermatol. 2001;145:1027–1028
  21. Serwin AB, Sokolowska M, Chodynicka B. Soluble tumor necrosis factor α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatol Photoimmunol Photomed. 2005;21:210–211
  22. Griffiths CEM, Boffa MJ, Gallatin WM, Martin S. Elevated levels of circulating intercellular adhesion molecule-3 (clCAM-3) in psoriasis. Acta Derm Venereol. 1996;76:2–5
  23. Serwin AB, Chodynicka B. Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. Biomarkers. 2007;12:599–607
  24. Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet. 2007;370:272–284
  25. Dolen JG, Mathur A. Undetectable interferon-alpha serum levels in a patient with atopic dermatitis. J Interferon Cytokine Res. 1995;15:973–975
  26. Novak N, Allam J-P, Hagemann T, Jenneck C, Laffer S, Valenta R, et al. Characterization of FcέR1-bearing CD123+ blood dendritic all antigen-2+ plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol. 2004;114:364–370
  27. Jullien D, Nicolas JF, Frappaz A, Thivolet J. Alpha interferon treatment in atopic dermatitis. Acta Derm Venereol. 1993;73:130–132
  28. Torrelo A, Harto A, Sendagorta E, Czarnetzki BM, Ledo A. Interferon-alpha therapy in atopic dermatitis. Acta Derm Venereol. 1992;72:370–372
  29. Gruschwitz MS, Peters KP, Heese A, Stosiek N, Koch Hu , Hornstein OP. Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema. Int Arch Allergy Immunol. 1993;101:20–30
  30. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. Arch Dis Child. 1992;67:277–279
  31. Pellegrino M, Minervini B, Musto P, Matera R, Greco A, Checchia de Ambrosio C. Tumour necrosis factor-alpha and interleukin-1 beta. Two possible mediators of allergic inflammation. Minerva Pediatr. 1996;48:309–312
  32. Laan MP, Koning H, Baert MR, Oranje AP, Buurman WA, Savelkoul HF, et al. Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children. Allergy. 1998;53:51–58
  33. Simon D, Braathen LR, Simon HU. Increased lipopolysaccharide-induced tumour necrosis factor-alpha, interferon-gamma and interleukin-10 production in atopic dermatitis. Br J Dermatol. 2007;157:583–586
  34. Takahashi T, Sasaki Y, Hama K, Furue M, Ishibashi Y. Production of Il-4, IL-2, IFN-gamma, and TNF-alpha by peripheral blood mononuclear cells of patients with atopic dermatitis. J Dermatol Sci. 1992;3:172–180
  35. Reinhold U, Pawelec G, Wehrmann W, Kukel S, Oehr P, Kreysel HW. Cytokine release from cultured peripheral blood mononuclear cells of patients with severe atopic dermatitis. Acta Derm Venereol. 1989;69:497–502
  36. Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol. 2006;19:237–240
  37. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52:522–526
  38. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004;3:315–318
  39. Giustizieri ML, Mascia F, Frezzolini A, De Pita O, Chinni LM, Giannetti A, et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T-cell derived cytokines. J Allergy Clin Immunol. 2001;107:871–877
  40. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and cotaxin) in patients with atopic dermatitis. Arch Dermatol Res. 2001;293:350–355
  41. van Beelen AJ, Teunissen MBM, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol. 2007;7:374–381
  42. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9:461–467
  43. Shehadeh N, Pollack S, Wildbaum G, Zohar Y, Shafat I, Makhoul R, et al. Beneficial autoantibody response to CCL3 participates in the regulation of type 1 diabetes mellitus and services as a novel biomarker for its diagnosis. J Immunol. 2009;182:8104–8109
  44. Cameron MJGA, Arreaza M, Grattan C, Meagher C, Sharif S, Burdick MD, et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J Immunol. 2000;165:1102–1110

PII: S0923-1811(09)00261-8

doi: 10.1016/j.jdermsci.2009.08.006

« Back Journal of Dermatological Science

Article in Press

Article Tools

* Image Usage & Resolution